PaxMedica, Inc. (PXMD)
| Market Cap | 43.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.35M |
| Shares Out | 12.04M |
| EPS (ttm) | 0.12 |
| PE Ratio | 30.17 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 721,688 |
| Open | 3.27 |
| Previous Close | 3.35 |
| Day's Range | 3.21 - 3.69 |
| 52-Week Range | 1.36 - 10.48 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 30, 2022 |
About PXMD
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic... [Read more]
Financial Performance
Financial StatementsNews
Why Is PaxMedica (PXMD) Stock Up Today?
What caused a pop-and-drop in PaxMedica (NASDAQ: PXMD) stock today? PaxMedica is in the headlines due to an arrangement that will reportedly generate over $3 million for the company.
PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners
Additional Capital Will Help Fund Development of PAX-101
Short Squeeze Stocks: 5 Stocks Wall Street Really DOESN'T Want to Win
Retail investors have taken a particular interest in potential short-squeeze stocks ever since the onset of the coronavirus pandemic. At that time, meme stock favorite GameStop (NYSE: GME) squeezed t...
Top 5 most-shorted stocks as of January 2023
The macroeconomic climate in 2022 and 2023 has had a negative impact on many equity investments. Fears of a possible recession and a gloomy attitude among investors have affected companies in precario...
PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event
Presentation on Thursday, January 26th, 2023 at 1:30 PM EST
PaxMedica, Inc. Launches Updated Corporate Website at PaxMedica.com
Update Offers More Comprehensive Understanding of PaxMedica's Focus, Process and Progress
PaxMedica to Present at the Benchmark Company's Upcoming Discovery One-on-One Investor Conference
TARRYTOWN, NY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug...
PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week
We're checking in on the top short squeeze stocks to watch this week as traders continue to have an interest in this part of the market! Short squeeze stocks are often subject to volatility with massi...
Why Is PaxMedica (PXMD) Stock Up 51% Today?
PaxMedica (NASDAQ: PXMD) stock is taking off on Friday after the biopharmaceutical company entered into an investment agreement with Lincoln Park Capital Fund. According to a press release, this cove...
PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital
-Agreement Provides Flexible Funding on Path to NDA Submission for PAX-101-
PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results
-PXMD Strengthened Executive Team and Board of Directors With Recent Appointments After IPO in August 2022-
PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission
Final Study Results are Expected in First Half of 2023
A Major Squeeze Is Brewing in PaxMedica (PXMD) Stock
PaxMedica (NASDAQ: PXMD) stock could be preparing for a short squeeze with recent signs showing potential for it to surge in price. Let's start off with the basics, which include the company completi...
PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer
Dr. Schwabe brings 30+ years of Clinical Experience in the Pharmaceutical Industry
PaxMedica Appoints Specialty Pharma Industry Leader Charles J. Casamento to Its Board of Directors
Founder of several public life sciences companies including Questcor, Osteologix and Indevus, Casamento will serve as an Independent Director
PaxMedica, Inc. Provides Corporate Update After IPO
-PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer-
Why Are Shipping Stocks Down Today?
Source: Darryl Brooks / Shutterstock.com Shipping stocks are sinking on Friday as reports come in that U.S. ports are still having trouble following turbulence during the pandemic. Shipping companies ...
Is PaxMedica (PXMD) Stock the Next Hot IPO?
IPO season continues today with another exciting entrant. PaxMedica (NASDAQ: PXMD) is the newest company to make its public debut.
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc.
Shares will Trade on Nasdaq Capital Market under Ticker Symbol "PXMD" TARRYTOWN, NY / ACCESSWIRE / August 26, 2022 / PaxMedica, Inc. (Nasdaq:PXMD), a clinical stage biopharmaceutical company focusing ...
PaxMedica, Inc. Announces Pricing of Initial Public Offering
Shares will Trade on Nasdaq Capital Market under Ticker Symbol “PXMD”